PineTree Therapeutics Revenue and Competitors

PineTree Therapeutics is a pre-clinical stage Biotech company headquartered in Cambridge MA. PineTree is focusing on developing two cutting edge platform technologies to create therapeutic assets for unmet needs in Oncology and Infectious diseases. PineTree’s goal is not only to cure, but also to prevent recurrence. Most patients always end up without any therapeutic option in the end by both drug refractory and drug resistant, and we believe our technologies will be the solution targeting patients in these unmet need categories. Our oncology platform, which is our main program, is called TAER-TAB, Tumor Associated Essential Receptor Targeting AntiBody. It is targeting untreatable solid tumors, especially the resistant tumor sector. It was developed to achieve efficacy both from targeted and Immuno-oncology therapy as a single molecule. There is a great development potential of the platform technology as multiple oncology pipelines. Our infectious disease platform is called ViTRAP, Virus Targeting Recombinant Agent Platform, which can be a potential biologic form of next “Penicillin” targeting over 30+ human infectious diseases. ViTRAP can be developed to cover all segments of viral diseases and/or developed for each segment separately, which is highly impactful to the society. Our two platform technologies come from one receptor, it serves two ends of cost effectiveness and productiveness of generating many assets.